Severance Hospital

Running trials

• Not yet recruiting

  Electrophysiological Dose-Response to Anterior Thalamic Deep Brain Stimulation in Drug-Resistant Focal Epilepsy

  NCT07912931· Source

• Recruiting

  Patient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA

  NCT07921888· Source

• Not yet recruiting

  Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation

  NCT07486739· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Recruiting

  A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

  NCT07154745· Phase 3· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Source

• Recruiting

  A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

  NCT07629115· Source

• Recruiting

  Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

  NCT07524101· Source

• Recruiting

  A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

  NCT07481357· Phase 1· Source

• Recruiting

  Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients

  NCT07371338· Phase 1· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Source

• Not yet recruiting

  AI-based Customized tDCS for Finger Motor Recovery After Subacute Stroke

  NCT07491029· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Enrolling by invitation

  A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

  NCT07423117· Phase 1· Source

• Recruiting

  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

  NCT07010497· Phase 2· Source

• Recruiting

  Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

  NCT07359105· Source

• Recruiting

  An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  NCT07469683· Phase 2· Source

• Recruiting

  Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

  NCT07449754· Phase 2· Source

• Recruiting

  A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

  NCT07187401· Phase 1/2· Source

• Recruiting

  A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer

  NCT07853209· Phase 3· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Recruiting

  Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease

  NCT07869238· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Source

• Not yet recruiting

  Dronedarone Rhythm Intervention for Early Atrial Fibrillation

  NCT07270848· Phase 4· Source

• Recruiting

  Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

  NCT06975787· Phase 1· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Source

• Enrolling by invitation

  The SMART Trial: Modified Single-Stapled Anastomosis in Laparoscopic or Robotic Low Anterior Resection for Rectal Cancer

  NCT07376980· Source

• Recruiting

  Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma

  NCT07235007· Source

• Not yet recruiting

  Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia

  NCT07247240· Phase 4· Source

• Not yet recruiting

  Thickness Map-Guided vs. Empirical PV Isolation Using Pulsed Field Ablation for Paroxysmal AF

  NCT07068646· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  NCT07049926· Phase 1/2· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· Source

• Not yet recruiting

  Effect of Bilateral vs. Unilateral Alveolar Recruitment on Gas Exchange in Lung Resection

  NCT07044661· Source

• Not yet recruiting

  A Phase 2 Study to Evaluate the Safety and Efficacy of BEY2153 in Patients with Early Alzheimer's Disease

  NCT06885567· Phase 2· Source

• Recruiting

  Streamlining Radioembolization for CCC and Metastatic Liver Cancer

  NCT07043387· Source

• Recruiting

  Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy

  NCT06984952· Source

• Recruiting

  Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

  NCT06975410· Phase 1/2· Source

• Recruiting

  Streamlining Radioembolization for Small HCC

  NCT06979219· Source

• Recruiting

  Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

  NCT06873763· Phase 1/2· Source

• Recruiting

  Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

  NCT06962098· Phase 2· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Source

• Active, not recruiting

  A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

  NCT06806852· Phase 1· Source

• Not yet recruiting

  An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

  NCT06855849· Phase 2· Source

• Recruiting

  A Multicenter Study of RUS NE

  NCT06868186· Source

• Recruiting

  Same-day Radioembolization for Large HCC

  NCT06944483· Source

• Recruiting

  Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

  NCT06528262· Phase 4· Source

• Recruiting

  Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

  NCT06773845· Phase 2· Source

• Recruiting

  A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

  NCT06687941· Phase 1· Source

• Recruiting

  Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

  NCT05439278· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer16 recruiting
• Liver and biliary tract cancer13 recruiting
• Colorectal cancer8 recruiting
• Gastric and esophageal cancer7 recruiting
• Ovarian cancer7 recruiting
• Childhood cancers6 recruiting
• Atrial fibrillation5 recruiting
• Head and neck cancer5 recruiting
• High blood pressure5 recruiting
• Type 2 diabetes5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Heart failure4 recruiting
• Chronic kidney disease3 recruiting
• Endometrial cancer3 recruiting
• Kidney cancer3 recruiting
• Multiple myeloma3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Alzheimer disease2 recruiting
• Bladder cancer2 recruiting
• Cervical cancer2 recruiting
• Coronary artery disease2 recruiting
• Lupus (SLE)2 recruiting
• Melanoma2 recruiting
• Metastatic breast cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• Parkinson disease2 recruiting
• Prostate cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sarcoma2 recruiting
• Stroke2 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glioblastoma1 recruiting
• Hepatitis B1 recruiting
• IgA nephropathy1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal muscular atrophy1 recruiting
• Thyroid cancer1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma

  NCT07043348· Source

• Completed

  Feasibility of RUS Lung in MITS

  NCT06952894· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

  NCT06747936· Phase 3· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

  NCT06329141· Phase 2· Source

• Terminated

  A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

  NCT06186076· Phase 1/2· Source

• Completed

  DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients

  NCT06406439· Source

• Completed

  A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

  NCT06024408· Phase 1· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Completed

  Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

  NCT06144788· Phase 2· Source

• Terminated

  GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

  NCT05998447· Phase 2· Source

• Completed

  Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam

  NCT06563063· Source

• Terminated

  A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

  NCT05660395· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

  NCT05930028· Phase 3· Source

• Completed

  Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia

  NCT05606094· Source

• Completed

  A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

  NCT05804747· Source

• Completed

  Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

  NCT05718375· Phase 2· Source

• Completed

  Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

  NCT05630768· Phase 4· Source

• Completed

  Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

  NCT05512377· Phase 2· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

  NCT07564726· Phase 3· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· Source

• Completed

  Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

  NCT05067634· Phase 3· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Source

• Completed

  Efficacy of Steroid Pulse Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF) Admitted in ER

  NCT04996303· Source

• Completed

  Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

  NCT04903314· Phase 1· Source

• Completed

  FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

  NCT04768686· Phase 2· Source

• Terminated

  Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

  NCT04820023· Phase 1/2· Source

• Completed

  Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

  NCT04484142· Phase 2· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Source

• Completed

  Shared Decision Making for Choosing renAl Replacement Therapy in Chronic Kidney Disease Patients

  NCT04976166· Source

• Completed

  KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  NCT04165083· Phase 2· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Source

• Completed

  Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

  NCT04387461· Phase 2· Source

• Completed

  Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation

  NCT04583046· Source

• Completed

  Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT04505436· Phase 2· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

  NCT04799496· Source

• Completed

  Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· Phase 3· Source

• Completed

  Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

  NCT04374877· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine

  NCT04289987· Phase 2· Source

• Completed

  Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

  NCT04248829· Phase 3· Source

• Completed

  Mid-Q Response Study

  NCT04180696· Source

Trial sites

• Severance Hospital2 trials
• Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine1 trial
• Division of Pulmonology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine1 trial
• Severance hospital190 trials
• Severance Hospital; Division of Hematology1 trial
• Severance Hospital - Shinchon1 trial
• Severance Hospital (Site 0080)4 trials
• Severance Hospital (Site 0192)1 trial
• Severance Hospital (Site 0652)1 trial
• Severance Hospital (Site 1063)1 trial
• Severance Hospital (Site 1802)1 trial
• Severance Hospital (Site 3802)1 trial
• Severance Hospital (Site 5003)1 trial
• Severance Hospital (Site 5802)1 trial
• Severance Hospital, Yonsei1 trial
• Severance Hospital, Yonsei Uni2 trials
• Severance Hospital, Yonsei University College of Medicine2 trials
• SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)1 trial
• Severance Hospital, Yonsei University (Site A)1 trial
• Severance Hospital, Yonsei University (Site B)1 trial
• Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center1 trial
• Yonsei University College of Medicine (Severance Hospital)3 trials
• Yonsei University, Severance Hospital (Seoul)1 trial
• Severance Hospital1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Ovarian cancer67 works · 11 trials
• Migraine33 works · 0 trials
• Idiopathic pulmonary fibrosis13 works · 4 trials
• Endometrial cancer13 works · 7 trials
• High blood pressure11 works · 8 trials
• Neuromyelitis optica (NMOSD)6 works · 0 trials